BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced the closing of its public offering of 1,199,448 shares of its common stock and pre-funded warrants to purchase up to 2,568,110 shares of common stock in a public offering at an offering price of $1.065 per share of common stock and $1.064 pre-funded warrant.

Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval of Augtyro™ for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Opthea Limited announced the successful completion of the institutional component of the capital raising announced on Wednesday, 12 June 2024.

Avidity Biosciences, Inc. announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share.

This study aimed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK)/ pharmacodynamics (PD) of ICP-B02 in relapsed/refractory (R/R) B-cell non-hodgkin lymphoma (NHL).

InduPro, Inc. announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund, Emerson Collective and Euclidean Capital.

BioLoomics, a biotechnology company that targets peptide-antibody chimeras to specific compartments inside of diseased cells, announced that Kurt Gish, Ph.D., has joined as the Chief Scientific Officer.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors.

Vaxart, Inc. announced that it received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle.